View in EDS

A longitudinal study of the associations of BDNF genotype and methylation with poststroke anxiety.

Saved in:
Bibliographic Details
Title: A longitudinal study of the associations of BDNF genotype and methylation with poststroke anxiety.
Authors: Kang, Hee‐Ju (AUTHOR), Kim, Kyu‐On (AUTHOR), Kim, Ju‐Wan (AUTHOR), Kim, Sung‐Wan (AUTHOR), Park, Man‐Seok (AUTHOR), Kim, Hye‐Ran (AUTHOR), Shin, Myung‐Geun (AUTHOR), Cho, Ki‐Hyun (AUTHOR), Kim, Jae‐Min (AUTHOR), Kang, Hee-Ju (AUTHOR), Kim, Kyu-On (AUTHOR), Kim, Ju-Wan (AUTHOR), Kim, Sung-Wan (AUTHOR), Park, Man-Seok (AUTHOR), Kim, Hye-Ran (AUTHOR), Shin, Myung-Geun (AUTHOR), Cho, Ki-Hyun (AUTHOR), Kim, Jae-Min (AUTHOR)
Source: International Journal of Geriatric Psychiatry. Nov2019, Vol. 34 Issue 11, p1706-1714. 9p. 1 Diagram, 3 Charts.
Subjects: Methylation, Brain-derived neurotrophic factor, Longitudinal method, Anxiety, Long-term potentiation, Genetic polymorphisms, Multivariate analysis, Nerve tissue proteins, Psychological tests, Research funding, Stroke, Genetic markers, Logistic regression analysis, Anxiety disorders, Disease prevalence, DNA methylation, Genotypes
Abstract: Background: Although the precise etiology of poststroke anxiety (PSA) has yet to be fully elucidated, it is known that brain-derived neurotrophic factor (BDNF) is important for neural plasticity and long-term potentiation, associated with the pathophysiology of anxiety. The expression of BDNF is regulated by epigenetic and genetic profiles. Thus, we investigated the association between BDNF methylation status and PSA at 2 weeks and 1 year after stroke while accounting for interactions with the BDNF Val66Met polymorphism.Methods: The baseline sample comprised 286 patients who were assessed at 2 weeks after stroke; of these patients, 222 (78%) were followed up with at 1 year after stroke. The presence of PSA was determined using the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS), and the effects of BDNF methylation status and polymorphisms on PSA status were assessed with multivariate logistic regression models.Results: The prevalence of PSA was slightly lower (27 [9.4%]) at baseline, and 35 (15.8%) patients were identified as having PSA at the 1-year follow-up. Stroke patients with a higher average methylation status were more likely to have PSA at 1 year. The BDNF Val66Met polymorphism was not independently associated with PSA during either the acute or chronic phase after stroke, but there was a significant interactive effect between BDNF methylation and genotype on PSA at 2 weeks.Conclusions: In this study, BDNF methylation in combination with the met/met BDNF polymorphism (Val66Met polymorphism) was associated with PSA. These findings may help identify patients at higher risk for PSA. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Geriatric Psychiatry is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:<bold>Background: </bold>Although the precise etiology of poststroke anxiety (PSA) has yet to be fully elucidated, it is known that brain-derived neurotrophic factor (BDNF) is important for neural plasticity and long-term potentiation, associated with the pathophysiology of anxiety. The expression of BDNF is regulated by epigenetic and genetic profiles. Thus, we investigated the association between BDNF methylation status and PSA at 2 weeks and 1 year after stroke while accounting for interactions with the BDNF Val66Met polymorphism.<bold>Methods: </bold>The baseline sample comprised 286 patients who were assessed at 2 weeks after stroke; of these patients, 222 (78%) were followed up with at 1 year after stroke. The presence of PSA was determined using the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS), and the effects of BDNF methylation status and polymorphisms on PSA status were assessed with multivariate logistic regression models.<bold>Results: </bold>The prevalence of PSA was slightly lower (27 [9.4%]) at baseline, and 35 (15.8%) patients were identified as having PSA at the 1-year follow-up. Stroke patients with a higher average methylation status were more likely to have PSA at 1 year. The BDNF Val66Met polymorphism was not independently associated with PSA during either the acute or chronic phase after stroke, but there was a significant interactive effect between BDNF methylation and genotype on PSA at 2 weeks.<bold>Conclusions: </bold>In this study, BDNF methylation in combination with the met/met BDNF polymorphism (Val66Met polymorphism) was associated with PSA. These findings may help identify patients at higher risk for PSA. [ABSTRACT FROM AUTHOR]
ISSN:08856230
DOI:10.1002/gps.5185